Literature DB >> 35339339

The importance of MRI for rectal cancer evaluation.

Maria Clara Fernandes1, Marc J Gollub2, Gina Brown3.   

Abstract

Magnetic resonance imaging (MRI) has gained increasing importance in the management of rectal cancer over the last two decades. The role of MRI in patients with rectal cancer has expanded beyond the tumor-node-metastasis (TNM) system in both staging and restaging scenarios and has contributed to identifying "high" and "low" risk features that can be used to tailor and personalize patient treatment; for instance, selecting the patients for neoadjuvant chemoradiation (NCRT) before the total mesorectal excision (TME) surgery based on risk of recurrence. Among those features, the status of the circumferential resection margin (CRM), extramural vascular invasion (EMVI), and tumor deposits (TD) have stood out. Moreover, MRI also has played a role in surgical planning, especially when the tumor is located in the low rectum, when the relationship between tumor and the anal canal is important to choose the best surgical approach, and in cases of locally advanced or recurrent tumors invading adjacent pelvic organs that may require more complex surgeries such as pelvic exenteration. As approaches using organ preservation emerge, including transanal local excision and "watch-and-wait", MRI may help in the patient selection for those treatments, follow up, and detection of tumor regrowth. Additionally, potential MRI-based prognostic and predictive biomarkers, such as quantitative and semi-quantitative metrics derived from functional sequences like diffusion-weighted imaging (DWI) and dynamic contrast-enhanced (DCE), and radiomics, are under investigation. This review provides an overview of the current role of MRI in rectal cancer in staging and restaging and highlights the main areas under investigation and future perspectives.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Magnetic resonance imaging; Rectal cancer

Mesh:

Year:  2022        PMID: 35339339      PMCID: PMC9464708          DOI: 10.1016/j.suronc.2022.101739

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   2.388


  138 in total

1.  Rectal Cancer: MR imaging of the mesorectal fascia and effect of chemoradiation on assessment of tumor involvement.

Authors:  Katja Oberholzer; Theodor Junginger; Achim Heintz; Andreas Kreft; Torsten Hansen; André Lollert; Maren Ebert; Christoph Düber
Journal:  J Magn Reson Imaging       Date:  2012-05-16       Impact factor: 4.813

2.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

3.  Diffusion-weighted MRI to assess response to chemoradiotherapy in rectal cancer: main interpretation pitfalls and their use for teaching.

Authors:  Doenja M J Lambregts; Miriam M van Heeswijk; Andrea Delli Pizzi; Saskia G C van Elderen; Luisa Andrade; Nicky H G M Peters; Peter A M Kint; Margreet Osinga-de Jong; Shandra Bipat; Rik Ooms; Max J Lahaye; Monique Maas; Geerard L Beets; Frans C H Bakers; Regina G H Beets-Tan
Journal:  Eur Radiol       Date:  2017-04-13       Impact factor: 5.315

4.  Mucinous rectal cancer: concepts and imaging challenges.

Authors:  Natally Horvat; Thomas A Hope; Perry J Pickhardt; Iva Petkovska
Journal:  Abdom Radiol (NY)       Date:  2019-11

5.  Dynamic contrast-enhanced MRI: Use in predicting pathological complete response to neoadjuvant chemoradiation in locally advanced rectal cancer.

Authors:  Tong Tong; Yiqun Sun; Marc J Gollub; Weijun Peng; Sanjun Cai; Zhen Zhang; Yajia Gu
Journal:  J Magn Reson Imaging       Date:  2015-02-05       Impact factor: 4.813

6.  Pathologic Complete Response in Rectal Cancer: Can We Detect It? Lessons Learned From a Proposed Randomized Trial of Watch-and-Wait Treatment of Rectal Cancer.

Authors:  Sergio Carlos Nahas; Caio Sergio Rizkallah Nahas; Carlos Frederico Sparapan Marques; Ulysses Ribeiro; Guilherme Cutait Cotti; Antonio Rocco Imperiale; Fernanda Cunha Capareli; Andre Tsin Chih Chen; Paulo M Hoff; Ivan Cecconello
Journal:  Dis Colon Rectum       Date:  2016-04       Impact factor: 4.585

7.  The value of hyoscine butylbromide in pelvic MRI.

Authors:  W Johnson; M B Taylor; B M Carrington; S C Bonington; R Swindell
Journal:  Clin Radiol       Date:  2007-08-20       Impact factor: 2.350

8.  The role of local excision in rectal cancer after complete response to neoadjuvant treatment.

Authors:  C Coco; A Manno; C Mattana; A Verbo; G Rizzo; V Valentini; M A Gambacorta; F M Vecchio; D D'Ugo
Journal:  Surg Oncol       Date:  2007-11-26       Impact factor: 3.279

Review 9.  Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review.

Authors:  J E Ryan; S K Warrier; A C Lynch; R G Ramsay; W A Phillips; A G Heriot
Journal:  Colorectal Dis       Date:  2016-03       Impact factor: 3.788

Review 10.  Prospective, Multicenter Validation Study of Magnetic Resonance Volumetry for Response Assessment After Preoperative Chemoradiation in Rectal Cancer: Can the Results in the Literature be Reproduced?

Authors:  Milou H Martens; Miriam M van Heeswijk; Joris J van den Broek; Sheng-Xiang Rao; Vincent Vandecaveye; Roy A Vliegen; Wilhelmina H Schreurs; Geerard L Beets; Doenja M J Lambregts; Regina G H Beets-Tan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-09-15       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.